CAR-T cell therapy: pharmacology

Evidence-based neurology checklist on car-t cell therapy: pharmacology: CAR-T cell agents Tisagenlecleucel Axicabtagene ciloleucel Lisocabtagene maraleucel Pharmacology Indications Neurotoxicity syndromes Acronym

CAR-T cell agents

  • Tisagenlecleucel
  • Axicabtagene ciloleucel 
  • Lisocabtagene maraleucel

Pharmacology

Indications

Neurotoxicity syndromes

Acronym

References

  1. Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020 (Online ahead of print).
  2. Strati P, Nastoupil LJ, Westin J, et al. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 2020; 4:3943-3951.
  3. Saleki K, Mohamadi MH, Alijanizadeh P, Rezaei N. Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol 2023 (Online ahead of print).
  4. Belin C, Devic P, Ayrignac X, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020; 10:18997. 
  5. Kuboki M, Umezawa Y, Motomura Y, et al. Severe motor weakness due to disturbance in peripheral nerves following tisagenlecleucel treatment. In Vivo 2021; 35:3407-3411.

Related checklists

Loading...